Dataset Information

Selective syntheses of no-carrier-added 2- and 3-[18F]fluorohalopyridines through the radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates.

ABSTRACT: No-carrier-added 2- and 3-[(18)F]fluorohalopyridines were readily synthesized as potentially useful labeling synthons for prospective PET radiotracers through the selective radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates, themselves conveniently prepared in a single pot from iodohalopyridines.

SUBMITTER: Chun JH

PROVIDER: S-EPMC4184153 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Selective syntheses of no-carrier-added 2- and 3-[18F]fluorohalopyridines through the radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates.

Chun Joong-Hyun JH Pike Victor W VW

Chemical communications (Cambridge, England) 20120830 79

No-carrier-added 2- and 3-[(18)F]fluorohalopyridines were readily synthesized as potentially useful labeling synthons for prospective PET radiotracers through the selective radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates, themselves conveniently prepared in a single pot from iodohalopyridines. ...[more]

PMID: 22932709

Similar Datasets

Project description:As a member of cyclic nucleotide phosphodiesterase (PDE) enzyme family, PDE10A is in charge of the degradation of cyclic adenosine (cAMP) and guanosine monophosphates (cGMP). While PDE10A is primarily expressed in the medium spiny neurons of the striatum, it has been implicated in a variety of neurological disorders. Indeed, inhibition of PDE10A has proven to be of potential use for the treatment of central nervous system (CNS) pathologies caused by dysfunction of the basal ganglia–of which the striatum constitutes the largest component. A PDE10A-targeted positron emission tomography (PET) radioligand would enable a better assessment of the pathophysiologic role of PDE10A, as well as confirm the relationship between target occupancy and administrated dose of a given drug candidate, thus accelerating the development of effective PDE10A inhibitors. In this study, we designed and synthesized a novel 18F-aryl PDE10A PET radioligand, codenamed [18F]P10A-1910 ([18F]9), in high radiochemical yield and molar activity via spirocyclic iodonium ylide-mediated radiofluorination. [18F]9 possessed good in vitro binding affinity (IC50 = 2.1 nmol/L) and selectivity towards PDE10A. Further, [18F]9 exhibited reasonable lipophilicity (logD = 3.50) and brain permeability (Papp > 10 × 10−6 cm/s in MDCK-MDR1 cells). PET imaging studies of [18F]9 revealed high striatal uptake and excellent in vivo specificity with reversible tracer kinetics. Preclinical studies in rodents revealed an improved plasma and brain stability of [18F]9 when compared to the current reference standard for PDE10A-targeted PET, [18F]MNI659. Further, dose–response experiments with a series of escalating doses of PDE10A inhibitor 1 in rhesus monkey brains confirmed the utility of [18F]9 for evaluating target occupancy in vivo in higher species. In conclusion, our results indicated that [18F]9 is a promising PDE10A PET radioligand for clinical translation. Graphical abstract A novel positron emission tomography (PET) ligand [18F]P10A-1910 realized PDE10A quantitative visualization and target engagement in vivo.Image 1

Dataset Information

Selective syntheses of no-carrier-added 2- and 3-[18F]fluorohalopyridines through the radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates.

Publications

Selective syntheses of no-carrier-added 2- and 3-[18F]fluorohalopyridines through the radiofluorination of halopyridinyl(4'-methoxyphenyl)iodonium tosylates.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure